ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 207
- Registration Number
- NCT00648999
- Locations
- 🇲🇽
Site Ref # / Investigator 4049, Mexico City, Distrito Federal, Mexico
🇲🇽Site Ref # / Investigator 4052, Oaxaca, Mexico
🇲🇽Site Ref # / Investigator 4055, Culiacan, Sinaloa, Mexico
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
- Conditions
- Nervous System NeoplasmsCentral Nervous System DiseasesBrain DiseasesBrain NeoplasmsNeoplasm Metastasis
- Interventions
- Radiation: Whole Brain Radiation Therapy
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 80
- Registration Number
- NCT00649207
- Locations
- 🇺🇸
Site Reference ID/Investigator# 52462, Chicago, Illinois, United States
🇺🇸Site Reference ID/Investigator# 24483, Kansas City, Kansas, United States
🇺🇸Site Reference ID/Investigator# 6344, Philadelphia, Pennsylvania, United States
Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 10
- Registration Number
- NCT00645177
- Locations
- 🇲🇽
Site Reference ID/Investigator# 10181, Durango, DGO., Mexico
🇺🇸Site Reference ID/Investigator# 8352, San Francisco, California, United States
🇺🇸Site Reference ID/Investigator# 6920, Harvey, Illinois, United States
Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Drug: placebo
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 121
- Registration Number
- NCT00640419
- Locations
- 🇺🇸
Site Reference ID/Investigator# 7536, Little Rock, Arkansas, United States
🇺🇸Site Reference ID/Investigator# 7954, Bradenton, Florida, United States
🇺🇸Site Reference ID/Investigator# 7559, Omaha, Nebraska, United States
Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 160
- Registration Number
- NCT00640185
- Locations
- 🇺🇸
Site Reference ID/Investigator# 7546, Lafayette, California, United States
🇺🇸Site Reference ID/Investigator# 7555, Memphis, Tennessee, United States
🇺🇸Site Reference ID/Investigator# 7545, Overland Park, Kansas, United States
Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer
- Interventions
- Drug: M200 (Volociximab)
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 138
- Registration Number
- NCT00635193
- Locations
- 🇷🇺
Site Reference ID/Investigator# 75347, St. Petersburg, Russian Federation
🇵🇱Site Reference ID/Investigator# 75345, Szczecin, Poland
🇺🇸Site Reference ID/Investigator# 75295, Corpus Christi, Texas, United States
Open Label Continuation Study in Moderate to Severe Psoriasis
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 2301
- Registration Number
- NCT00626002
- Locations
- 🇺🇸
Site Reference ID/Investigator# 7899, Columbus, Ohio, United States
🇺🇸Site Reference ID/Investigator# 7239, Los Angeles, California, United States
🇺🇸Site Reference ID/Investigator# 7498, Dallas, Texas, United States
An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 155
- Registration Number
- NCT00619866
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
- Conditions
- Coronary Heart DiseaseDyslipidemiaCoronary Artery Disease
- Interventions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 682
- Registration Number
- NCT00616772
- Locations
- 🇺🇸
Site Reference ID/Investigator# 7098, Tempe, Arizona, United States
🇺🇸Site Reference ID/Investigator# 20882, Kissimmee, Florida, United States
🇺🇸Site Reference ID/Investigator# 19321, Melbourne, Florida, United States
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: adalimumab
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 592
- Registration Number
- NCT00573794